Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Relapsed/Refractory

At the 2021 annual meeting of the American Society of Hematology, CLL Society’s Medical Advisory Board Co-Chair Dr. Alex Danilov interviewed Dr. Arnon P. Kater, the lead author of this article and Chair of the Dutch CLL society, to discuss the evolving results of the Murano trial four years later.
Some see CLL/SLL as a solved problem. But unfortunately, we know better. This abstract from the European Hematology Association (EHA) Annual Congress in 2022 reinforced one of our greatest unsolved problems: what happens following treatment with a covalent BTK and BCL2 inhibitor.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, we received the four-year follow-up data update on the ASCEND trial. This trial compared acalabrutinib (acala) to the treating doctor’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia.